Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YDLQR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CD206-NAMPT inhibitor-based antibody drug conjugate
|
|||||
| Synonyms |
CD206-NAMPT inhibitor-based antibody drug conjugate (Bayer)
Click to Show/Hide
|
|||||
| Organization |
Bayer AG
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Hematologic cancer [ICD11:2B3Z]
Investigative
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Investigative
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Macrophage mannose receptor 1 (MRC1)
|
Antigen Info | ||||
| Payload Name |
NAMPT toxophore
|
Payload Info | ||||
| Therapeutic Target |
Nicotinamide phosphoribosyltransferase (NAMPT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Antibodies were conjugated to a NAMPT toxophore by Cys-conjugation using non-cleavable linker.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.